The application period has now closed. Apply today to join survivors, caregivers and activists across the country to affect change for those impacted by ovarian cancer. Advocate Leaders will learn how to educate federal and state policymakers about the disease, protect funding for lifesaving research, and fight for expanded access to treatment and care. No legislative or … Continued
Dr. Liya Ding, of Dana-Farber Cancer Institute, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With her project, “Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer,” Dr. Ding is focusing on PARP inhibitors — some of the most effective drug therapies available for ovarian cancer, but that often come with a … Continued
Dr. Bojana Stefanovska, at University of Minnesota Twin Cities, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. Her project, “APOBEC3B and DNA Repair as Synthetic Lethal Combinations in CCOC,” explores DNA repair as a potential treatment avenue for clear cell ovarian carcinoma (CCOC). What initially sparked your interest in science? … Continued
Dear Friends, I hope this finds you all well, staying safe, and enjoying preparations for a lovely holiday. Whether you’re gathering with loved ones or holding them in your heart as you celebrate, I wish you warmth and joy. With the busy holiday season just around the corner, I’m grateful for this moment to reflect on … Continued
As we head into the Thanksgiving holiday, we have much to be thankful for … an embracing and strong survivor community, supporters who remain ever committed to the cause, and brilliant grantees who are making strides every day in the search for better treatments and a cure for ovarian cancer. Here’s a roundup of what’s … Continued
Clinical trials are fundamental to the discovery of new and better therapies in the fight against ovarian cancer. Yet enrollment and widespread availability remain a challenge. To address both financial barriers and inequity in participation, OCRA is urging Congress to pass the DIVERSE (Diversifying Investigations Via Equitable Research Studies for Everyone) Trials Act (H.R. 5030/S. … Continued
The following is a press release from University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, and Magee-Womens Research Institute PITTSBURGH, Nov. 12, 2021 – Immune checkpoint inhibitors are a type of cancer treatment that help the immune system’s T cells recognize and attack tumors. But these immunotherapy drugs aren’t effective against all cancers. In … Continued
Have we got a roundup in store! You heard from us a lot in September (thanks to you, we surpassed our Ovarian Cancer Awareness Month fundraising goal!) and there’s still so much to report … research progress, a brand new clinical trial initiative, our upcoming Fall Advocacy Day, and the list goes on. Read on … Continued
November 15-16, 2021 | Register Today! Are you passionate about issues affecting the ovarian cancer community? Now is your chance to have your voice heard at the highest levels — without ever leaving home! OCRA’s Virtual Advocacy Day is a rare opportunity to communicate directly with your Members of Congress, and advocate for federal programs … Continued
Sridevi Challa, PhD, an OCRA grantee at UT Southwestern, is on the receiving end of some major accolades. She is the lead author of a study that dozens of news outlets are describing as having found the “Achilles’ Heel” of ovarian cancer cells. This opens the door for new research in biomarkers and the development … Continued
OCRA grantee Dr. Sumegha Mitra of Indiana University and colleagues have identified the mechanism by which a specific deubiquitinating enzyme known as UCHL1 promotes the growth of high-grade serous ovarian cancer in some patients. This discovery may aid in the development of future ovarian cancer therapies, as it points to the potential effectiveness of a targeted inhibitor … Continued
LOS ANGELES – (BUSINESS WIRE)–Global Coalition for Adaptive Research (GCAR) announces a new clinical trial initiative, Ovarian CanceRxTM. This innovative trial, referred to as an adaptive platform trial, is designed to test multiple drugs simultaneously against the standard of care treatments to rapidly test and deliver new therapies to patients with advanced ovarian cancer or recurrent … Continued
Get email updates about research news, action alerts, and ways to join the fight.
